AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16792136 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral alfacalcidol (1 microg given 6 days/week)
Number of subjects: 34
Study 12755658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 34
Study 12755658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11113728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 30
Study 11113728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1729064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 12
Study 1729064 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 12
Study 1729064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and salbutamol
Number of subjects: 12
Study 1729064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1729064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 12
Study 6398510 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dihydroergotamine + 5000 U heparin
Number of subjects: 46
Study 6398510 — intervention group
Group type: COMPARATOR
Intervention: 5000 U heparin alone (controls)
Number of subjects: 46
Study 30655255 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom administration of a standard dose of gadobutrol
Number of subjects: 83
Study 30607120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity (hf) e-learning module
Number of subjects: 18
Study 30607120 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity (lf) e-learning module
Number of subjects: 18
Study 30607120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity (hf) and Low-fidelity (lf) e-learning modules
Number of subjects: 18
Study 27109326 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 35
Study 27109326 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental CBT
Number of subjects: 35
Study 27109326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-therapy response level
Number of subjects: 35
Study 24670078 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-inclined seatpan
Number of subjects: 12
Study 24670078 — intervention group
Group type: COMPARATOR
Intervention: Backrest
Number of subjects: 12
Study 22151772 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback cues
Number of subjects: 10
Study 22151772 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback cues
Number of subjects: 10
Study 20876405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pine bark extract (200 mg/day)
Number of subjects: 130
Study 20876405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 17572643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen (665 mg modified-release tablets, three times a day for five days)
Number of subjects: 78
Study 17572643 — intervention group
Group type: COMPARATOR
Intervention: As needed acetaminophen (665 mg tablets as needed)
Number of subjects: 78
Study 17572643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen
Number of subjects: 78
Study 17572643 — intervention group
Group type: COMPARATOR
Intervention: As needed acetaminophen
Number of subjects: 78
Study 17572643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 16036010 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecardiology
Number of subjects: 200
Study 16036010 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 11870512 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary specialist genetics service
Number of subjects: 735
Study 11870512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical consultation with specialist genetic risk assessment
Number of subjects: 735
Study 11870512 — intervention group
Group type: COMPARATOR
Intervention: Surgical consultation without specialist genetic risk assessment
Number of subjects: 735
Study 11870512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical consultation with or without specialist genetic risk assessment
Number of subjects: 735
Study 10340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Community optometrists
Number of subjects: 405
Study 10340981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital eye service
Number of subjects: 405
Study 10340981 — intervention group
Group type: COMPARATOR
Intervention: Research clinic reference standard
Number of subjects: 405
Study 8722438 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice a day orally for 12 months)
Number of subjects: 16
Study 1824732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (3.6 mg of goserelin acetate)
Number of subjects: 164
Study 1824732 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 164
Study 1824732 — intervention group
Group type: COMPARATOR
Intervention: Zoladex and Orchiectomy
Number of subjects: 164
Study 6414571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (ASA/DPM)
Number of subjects: 67
Study 6414571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31836306 — intervention group
Group type: EXPERIMENTAL
Intervention: Point‐of‐Care systems
Number of subjects: 0
Study 31836306 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized laboratory
Number of subjects: 0
Study 29190378 — intervention group
Group type: COMPARATOR
Intervention: English-text-and-pictograms
Number of subjects: 1414
Study 29190378 — intervention group
Group type: COMPARATOR
Intervention: Bilingual-text
Number of subjects: 1414
Study 29190378 — intervention group
Group type: COMPARATOR
Intervention: Bilingual-text-and-pictograms
Number of subjects: 1414
Study 28658250 — intervention group
Group type: EXPERIMENTAL
Intervention: Public
Number of subjects: 0
Study 28658250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chefs and catering students
Number of subjects: 0
Study 28658250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chefs in fine‐dining establishments
Number of subjects: 0
Study 28658250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chefs in award-winning restaurants
Number of subjects: 0
Study 28658250 — intervention group
Group type: COMPARATOR
Intervention: Price of a meal and Food Hygiene Rating Score
Number of subjects: 0
Study 26907864 — intervention group
Group type: COMPARATOR
Intervention: Recalling a prior DMV experience
Number of subjects: 0
Study 26907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of negative emotion
Number of subjects: 0
Study 26907864 — intervention group
Group type: COMPARATOR
Intervention: Recalling a frustrating DMV experience
Number of subjects: 0
Study 25127244 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV10 three plus one and two plus one schedules combined
Number of subjects: 47366
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days (900 mg once daily)
Number of subjects: 318
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 200 days (900 mg once daily)
Number of subjects: 318
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days
Number of subjects: 318
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 200 days
Number of subjects: 318
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients meeting resistance analysis criteria (RAC) during prophylaxis
Number of subjects: 318
Study 22237003 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not meeting RAC post-prophylaxis
Number of subjects: 318
Study 19931952 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (2007 southern hemisphere influenza vaccine); coverage among ACF residents ranged from 59% to 100%.
Number of subjects: 0
Study 17462091 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care Plus Musculoskeletal Physiotherapy Treatment (UCMT)
Number of subjects: 0
Study 17462091 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) administered by the General Practitioner (GP)
Number of subjects: 0
Study 16302629 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary first rib resection (TFRR)
Number of subjects: 55
Study 16302629 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular neuroplasty of brachial plexus (SNBP)
Number of subjects: 55
Study 12042192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 101
Study 12042192 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 12042192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 101
Study 12042192 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 101
Study 9733427 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction treatment (20 sessions)
Number of subjects: 19
Study 9733427 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing treatment (20 sessions)
Number of subjects: 19
Study 9733427 — intervention group
Group type: COMPARATOR
Intervention: Combined groups (Distraction and Focusing)
Number of subjects: 19
Study 9733427 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusers
Number of subjects: 19
Study 9733427 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracters
Number of subjects: 19
Study 8555030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride 50 mg once daily for 4 weeks
Number of subjects: 48
Study 8555030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1723447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 10
Study 1723447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 10
Study 1723447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HCTZ and nitrendipine
Number of subjects: 10
Study 6781321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem 90 mg
Number of subjects: 9
Study 6781321 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 9
Study 6781321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin 0.3 mg
Number of subjects: 9
Study 30883589 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 1: Direct contact attempts by up to 12 systematically timed phone calls
Number of subjects: 370
Study 30883589 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 2: Personalized pre-notification letter to arrange for scheduled phone call interviews
Number of subjects: 370
Study 30883589 — intervention group
Group type: COMPARATOR
Intervention: Validation population using Strategy 1
Number of subjects: 370
Study 28029390 — intervention group
Group type: EXPERIMENTAL
Intervention: Olumacostat glasaretil (OG) 7.5% gel
Number of subjects: 108
Study 28029390 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 108
Study 25017924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral low-dose hormone therapy (estradiol 1 mg + drospirenone 2 mg/day) for 3 months
Number of subjects: 44
Study 25017924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-oral hormone therapy (1.5 mg/day percutaneous 17β-estradiol gel or equivalent for nasal route for 3 months followed by 200 mg/day micronized progesterone by the vaginal route for 14 days during each menstrual period)
Number of subjects: 44
Study 25017924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral hormone therapy
Number of subjects: 44
Study 25017924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-oral hormone therapy
Number of subjects: 44
Study 23830706 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping group 1 (KT1)
Number of subjects: 49
Study 23830706 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping group 2 (KT2)
Number of subjects: 49
Study 23830706 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesiotaping (KT3)
Number of subjects: 49
Study 23830706 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of KT1 and KT2
Number of subjects: 49
Study 21484002 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation program with education and practical training along with home visits by a community health nurse
Number of subjects: 80
Study 21484002 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiac rehabilitation program in the rehabilitation center (Control)
Number of subjects: 80
Study 19330665 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior doctor-led prescribing tutorial
Number of subjects: 271
Study 17578315 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengxueling (SXL), 60 mg twice a day for two weeks, then doubled if no marked rise in platelet count, administered for another two weeks.
Number of subjects: 69
Study 17578315 — intervention group
Group type: COMPARATOR
Intervention: Ampeptide elemente, 0.4 g three times a day for two weeks, then adjusted to 0.2 g each time for a total of 1.8 g a day for two more weeks.
Number of subjects: 69
Study 15272511 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel (test)
Number of subjects: 20
Study 15272511 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (control)
Number of subjects: 20
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSc patients with Barnett type III
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSD patients
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of SP-D in SSc patients with anti-topoisomerase I antibodies
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with pulmonary fibrosis severity
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with vital capacity and %DLco
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of SP-D levels with forced expiratory volume (FEV1.0%)
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-therapy with photopheresis
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum levels of SP-D and KL-6
Number of subjects: 219
Study 11603386 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of SP-D in the group of collagen diseases
Number of subjects: 219
Study 11603386 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SP-D levels between SSc patients and other collagen diseases and dermatitis
Number of subjects: 219
Study 9640884 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream (1%)
Number of subjects: 100
Study 9640884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8081786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous OKT3 for seven days
Number of subjects: 0
Study 8081786 — intervention group
Group type: COMPARATOR
Intervention: Intravenous CsA
Number of subjects: 0
Study 8081786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing rejection episodes
Number of subjects: 0
Study 8081786 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving OKT3
Number of subjects: 0
Study 2510273 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ulcer prostaglandins (misoprostol, enprostil, rioprostil)
Number of subjects: 5000
Study 2510273 — intervention group
Group type: COMPARATOR
Intervention: H2-blockers
Number of subjects: 5000
Study 2510273 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ulcer prostaglandins
Number of subjects: 5000
Study 32930 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with higher osmolar load (539 mosm/1) and containing protein hydrolysate
Number of subjects: 27
Study 32930 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas with varying osmolarity and MCT content
Number of subjects: 27
Study 31461720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricothyroid method
Number of subjects: 500
Study 27161196 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoinsight psychological enhancing method (art video shown before rehabilitation sessions)
Number of subjects: 110
Study 27161196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video support)
Number of subjects: 110
Study 25564143 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily for 4 days
Number of subjects: 34
Study 25564143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23299606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 71
Study 23299606 — intervention group
Group type: COMPARATOR
Intervention: Continuous morphine
Number of subjects: 71
Study 21856767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 261
Study 21856767 — intervention group
Group type: EXPERIMENTAL
Intervention: SRE gene signature
Number of subjects: 261
Study 19726374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and Hp eradication (group A, 51 cases)
Number of subjects: 93
Study 19726374 — intervention group
Group type: COMPARATOR
Intervention: Prednisone without Hp eradication (group B, 42 cases)
Number of subjects: 93
Study 17488771 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60 mg acute loading dose prior to PCI
Number of subjects: 266
Study 17488771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMZ)
Number of subjects: 266
Study 15487709 — intervention group
Group type: EXPERIMENTAL
Intervention: Native sodium hyaluronate
Number of subjects: 40
Study 15487709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐linked hylan G‐F 20
Number of subjects: 40
Study 11742047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg once daily for 12 months)
Number of subjects: 627
Study 11742047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (3 months) followed by placebo (9 months)
Number of subjects: 627
Study 11742047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 months)
Number of subjects: 627
Study 11742047 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (at 52 weeks)
Number of subjects: 627
Study 9631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy ratings during therapy
Number of subjects: 0
Study 9631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Object Relations (QOR)
Number of subjects: 0
Study 9631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 0
Study 8164015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 250
Study 8164015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 3495775 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoids-acellular pertussis vaccine
Number of subjects: 120
Study 3495775 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus toxoids-whole cell pertussis vaccine
Number of subjects: 120
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with large green lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with small green lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with split red lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato with large green lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato with small green lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato with split red lentils
Number of subjects: 48
Study 29659967 — intervention group
Group type: COMPARATOR
Intervention: Potato alone
Number of subjects: 48
Study 29659967 — intervention group
Group type: COMPARATOR
Intervention: Rice alone
Number of subjects: 48
Study 28501812 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted physiotherapy assessment and treatment
Number of subjects: 48
Study 28501812 — intervention group
Group type: COMPARATOR
Intervention: Evidence informed usual physiotherapy care
Number of subjects: 48
Study 25661476 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy diet
Number of subjects: 15
Study 25661476 — intervention group
Group type: COMPARATOR
Intervention: Low-fat dairy diet
Number of subjects: 15
Study 24142616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoxen® Lenitiva cream
Number of subjects: 80
Study 24142616 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone aceponate 0.1% based cream
Number of subjects: 80
Study 21945310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel followed by carboplatin (sDC)
Number of subjects: 148
Study 21945310 — intervention group
Group type: COMPARATOR
Intervention: Combination docetaxel and carboplatin (cDC)
Number of subjects: 148
Study 19099676 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg/d
Number of subjects: 84
Study 19099676 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast 5 mg, once at bedtime for 6 months
Number of subjects: 84
Study 16971666 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) expression
Number of subjects: 967
Study 16971666 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 967
Study 14570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Demands of divided attention during delay periods with interruptions (Experiment 1)
Number of subjects: 3
Study 14570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic rehearsal and implementation intention strategies (Experiments 2 and 3)
Number of subjects: 3
Study 11103758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alpha2b
Number of subjects: 58
Study 11103758 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alpha2b (active control)
Number of subjects: 58
Study 8932888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 40